Findings

What do systematic reviews say?

764 questions · 795 findings · 110 reviews

No studies found 202 · 25.4%GRADE not reported 100 · 12.6%Very low 225 · 28.3%Low 155 · 19.5%Moderate 85 · 10.7%High 28 · 3.5%

Rate of decline of Norris Scale ‐ Norris Bulbar (riluzole 100 mg) · patients with ALS/MND

1 finding from 1 review

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) 2012 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 742 participants
High

Adverse event: nausea · patients with ALS/MND

The intervention leads to higher adverse event: nausea (high certainty).

1 finding from 1 review

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) 2012 · Cochrane Headline outcomes only
RR 1.55 [1.06, 2.28]
3 studies · 801 participants
High

Adverse event: asthenia · patients with ALS/MND

The intervention leads to higher adverse event: asthenia (high certainty).

1 finding from 1 review

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) 2012 · Cochrane Headline outcomes only
RR 1.5 [1.07, 2.12]
3 studies · 801 participants
High

Adverse event: 3‐fold increase in alanine transferase · patients with ALS/MND

The intervention leads to higher adverse event: 3‐fold increase in alanine transferase (high certainty).

1 finding from 1 review

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) 2012 · Cochrane Headline outcomes only
RR 2.62 [1.59, 4.31]
3 studies · 801 participants
High